$AGIO
AGIOS PHARMACEUTICALS, INC.

2023 Q2 Form 10-Q Financial Statement

#000143922223000065 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $6.712M $5.609M $832.0K
YoY Change 20.24% 574.16%
Cost Of Revenue $1.108M $554.0K $339.0K
YoY Change 154.71% 63.42%
Gross Profit $5.604M $5.055M $493.0K
YoY Change 8.88% 925.35%
Gross Profit Margin 83.49% 90.12% 59.25%
Selling, General & Admin $30.41M $28.37M $31.52M
YoY Change 7.59% -9.99% -6.07%
% of Gross Profit 542.63% 561.17% 6392.49%
Research & Development $68.90M $67.30M $70.12M
YoY Change -7.55% -4.02% 21.6%
% of Gross Profit 1229.39% 1331.37% 14223.73%
Depreciation & Amortization $1.807M $1.790M $2.478M
YoY Change -21.13% -27.76% -0.88%
% of Gross Profit 32.24% 35.41% 502.64%
Operating Expenses $99.30M $95.67M $70.12M
YoY Change 33.25% 36.43% 21.6%
Operating Profit -$93.70M -$90.61M -$101.1M
YoY Change -4.04% -10.41% 10.88%
Interest Expense $8.254M $8.091M $694.0K
YoY Change 360.35% 1065.85% 104.12%
% of Operating Profit
Other Income/Expense, Net $1.640M $1.504M $2.973M
YoY Change 22.66% -49.41%
Pretax Income -$83.81M -$81.02M -$94.77M
YoY Change -8.71% -14.51% 4.29%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$83.81M -$81.02M -$94.77M
YoY Change -8.71% -14.51% -105.06%
Net Earnings / Revenue -1248.6% -1444.43% -11391.11%
Basic Earnings Per Share -$1.51 -$1.47 -$1.74
Diluted Earnings Per Share -$1.51 -$1.47 -$1.74
COMMON SHARES
Basic Shares Outstanding 55.58M shares 55.29M shares 54.56M shares
Diluted Shares Outstanding 55.60M shares 55.27M shares 54.56M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $702.6M $739.2M $923.5M
YoY Change -14.25% -19.96% -60.46%
Cash & Equivalents $84.75M $104.1M $80.03M
Short-Term Investments $617.8M $635.1M $843.5M
Other Short-Term Assets $36.75M $39.30M $43.23M
YoY Change -13.19% -9.08% 121.67%
Inventory $15.67M $11.37M $2.485M
Prepaid Expenses
Receivables $2.251M $1.778M $540.0K
Other Receivables $0.00 $0.00 $5.365M
Total Short-Term Assets $757.2M $791.7M $975.1M
YoY Change -12.96% -18.82% -58.59%
LONG-TERM ASSETS
Property, Plant & Equipment $79.50M $21.44M $29.20M
YoY Change 190.34% -26.57% 0.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $244.4M $271.7M $255.8M
YoY Change -12.99% 6.21% 1084.43%
Other Assets $4.057M $3.956M $2.900M
YoY Change 2.58% 36.41%
Total Long-Term Assets $327.9M $359.6M $360.7M
YoY Change -14.26% -0.3% 170.56%
TOTAL ASSETS
Total Short-Term Assets $757.2M $791.7M $975.1M
Total Long-Term Assets $327.9M $359.6M $360.7M
Total Assets $1.085B $1.151B $1.336B
YoY Change -13.36% -13.82% -46.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.63M $8.662M $11.55M
YoY Change 49.24% -25.01% -77.45%
Accrued Expenses $43.52M $22.46M $19.75M
YoY Change 53.31% 13.73% -16.33%
Deferred Revenue $2.500M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $250.0K
YoY Change -16.67%
Total Short-Term Liabilities $55.14M $45.11M $45.79M
YoY Change 13.94% -1.48% -52.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $276.0K
YoY Change -100.0% -100.0% 38.0%
Other Long-Term Liabilities $65.78M $1.313M $82.34M
YoY Change 6134.69% -98.41% -13.42%
Total Long-Term Liabilities $65.78M $1.313M $82.61M
YoY Change 6134.69% -98.41% -13.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $55.14M $45.11M $45.79M
Total Long-Term Liabilities $65.78M $1.313M $82.61M
Total Liabilities $120.9M $114.8M $128.4M
YoY Change -5.83% -10.62% -33.05%
SHAREHOLDERS EQUITY
Retained Earnings -$635.4M -$551.6M -$333.5M
YoY Change 49.38% 65.37% -1181.15%
Common Stock $2.411B $2.399B $2.351B
YoY Change 2.05% 2.03% 3.77%
Preferred Stock
YoY Change
Treasury Stock (at cost) $802.5M $802.5M $802.5M
YoY Change 0.0% 0.0%
Treasury Stock Shares 16.22M shares 16.22M shares
Shareholders Equity $964.2M $1.037B $1.207B
YoY Change
Total Liabilities & Shareholders Equity $1.085B $1.151B $1.336B
YoY Change -13.36% -13.82% -46.32%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$83.81M -$81.02M -$94.77M
YoY Change -8.71% -14.51% -105.06%
Depreciation, Depletion And Amortization $1.807M $1.790M $2.478M
YoY Change -21.13% -27.76% -0.88%
Cash From Operating Activities -$66.75M -$95.18M -$97.74M
YoY Change -10.08% -2.61% -19.06%
INVESTING ACTIVITIES
Capital Expenditures -$3.000K $399.0K $2.804M
YoY Change -99.84% -85.77% 177.08%
Acquisitions
YoY Change
Other Investing Activities $47.12M $58.00M -$23.77M
YoY Change -44.39% -343.99% -101.27%
Cash From Investing Activities $47.13M $57.60M -$26.57M
YoY Change -43.09% -316.75% -101.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 237.0K $2.467M $1.208M
YoY Change -453.73% 104.22% -83.36%
NET CHANGE
Cash From Operating Activities -66.75M -$95.18M -$97.74M
Cash From Investing Activities 47.13M $57.60M -$26.57M
Cash From Financing Activities 237.0K $2.467M $1.208M
Net Change In Cash -19.39M -$35.12M -$123.1M
YoY Change -327.62% -71.47% -106.99%
FREE CASH FLOW
Cash From Operating Activities -$66.75M -$95.18M -$97.74M
Capital Expenditures -$3.000K $399.0K $2.804M
Free Cash Flow -$66.75M -$95.58M -$100.5M
YoY Change -7.69% -4.93% -17.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001439222
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36014
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
AGIOS PHARMACEUTICALS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-0662915
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
88 Sidney Street
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2023Q1 dei City Area Code
CityAreaCode
617
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
649-8600
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
AGIO
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55580791 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104139000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
139259000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
635062000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
643860000 usd
CY2023Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
1778000 usd
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
2206000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
11374000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
8492000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
39303000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
38955000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
791656000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
832772000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
271727000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
313874000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
62521000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
65129000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21438000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22987000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3956000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3956000 usd
CY2023Q1 us-gaap Assets
Assets
1151298000 usd
CY2022Q4 us-gaap Assets
Assets
1238718000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
8662000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
18616000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22459000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30350000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
13992000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
13663000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
45113000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62629000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
68346000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
71996000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1313000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3279000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
114772000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
137904000 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 usd
CY2022Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71757778 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55541367 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71256118 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55039707 shares
CY2023Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
72000 usd
CY2022Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
71000 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2398930000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2386325000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-8411000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-12535000 usd
CY2023Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
16216411 shares
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
16216411 shares
CY2023Q1 us-gaap Treasury Stock Value
TreasuryStockValue
802486000 usd
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
802486000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-551579000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-470561000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1036526000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1100814000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1151298000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1238718000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5609000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
832000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
554000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
339000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
67301000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70123000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
28367000 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31515000 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
96222000 usd
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
101977000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-90613000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-101145000 usd
CY2023Q1 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
0 usd
CY2022Q1 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
2704000 usd
CY2023Q1 us-gaap Investment Income Net
InvestmentIncomeNet
8091000 usd
CY2022Q1 us-gaap Investment Income Net
InvestmentIncomeNet
694000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1504000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2973000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-81018000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-94774000 usd
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.47
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.47
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.74
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.74
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55265390 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55265390 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54555467 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54555467 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-81018000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-94774000 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4124000 usd
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6547000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76894000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-101321000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1100814000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
4124000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2467000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10139000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-81018000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1036526000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1291975000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
-6547000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1289000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15510000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-94774000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1207453000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-81018000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-94774000 usd
CY2023Q1 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
1790000 usd
CY2022Q1 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
2478000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10139000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
15510000 usd
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2776000 usd
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1150000 usd
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
150000 usd
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2608000 usd
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2436000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-428000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
540000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2882000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2485000 usd
CY2023Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 usd
CY2022Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
987000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
348000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3391000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9796000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5007000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-7891000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-12220000 usd
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2500000 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3321000 usd
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2405000 usd
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1966000 usd
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-95183000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-97735000 usd
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
128351000 usd
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
355916000 usd
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
186196000 usd
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
332147000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
399000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2804000 usd
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
150000 usd
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
57596000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26573000 usd
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0 usd
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
81000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2467000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1289000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2467000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1208000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-35120000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-123100000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
139259000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
203126000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104139000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80026000 usd
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1536000 usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
1842000 usd
CY2022 agio Gain Loss On Sale Of Contingent Payments
GainLossOnSaleOfContingentPayments
127900000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
99000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
12634000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic, or other pandemics or public health emergencies, may in the future directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div>
CY2023Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
1000000000 usd
CY2022Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
915200000 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
307000 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
8718000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
906789000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
970269000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
957734000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
221 security
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
259 security
CY2022Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
779300000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
868200000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0 security
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0 security
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
10412000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
7550000 usd
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
962000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
942000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
11374000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
8492000 usd
CY2023Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P5Y
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
3807000 usd
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
3807000 usd
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
4520000 usd
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
3776000 usd
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y10M24D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y2M12D
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
4459000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
12131000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
18660000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
19507000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
20151000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
20755000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3479000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
94683000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12345000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
82338000 usd
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
3266000 usd
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
1101000 usd
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
8826000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6651000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
18105000 usd
CY2023Q1 agio Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
11110000 usd
CY2022Q4 agio Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
8425000 usd
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1520000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2435000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3178000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1385000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22459000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30350000 usd
CY2022Q4 agio Contract With Customer Contractual Adjustment Reserve
ContractWithCustomerContractualAdjustmentReserve
65000 usd
CY2022Q4 agio Contract With Customer Rebate Reserve
ContractWithCustomerRebateReserve
573000 usd
CY2022Q4 agio Contract With Customer Right To Recover Product Reserve
ContractWithCustomerRightToRecoverProductReserve
133000 usd
CY2022Q4 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
771000 usd
CY2023Q1 agio Current Year Provision For Contractual Adjustments
CurrentYearProvisionForContractualAdjustments
291000 usd
CY2023Q1 agio Current Year Provisions For Rebate Reserve
CurrentYearProvisionsForRebateReserve
418000 usd
CY2023Q1 agio Provision For Right To Recover Product In Current Year
ProvisionForRightToRecoverProductInCurrentYear
64000 usd
CY2023Q1 agio Contract With Customer Current Year Reserve Provisions
ContractWithCustomerCurrentYearReserveProvisions
773000 usd
CY2023Q1 agio Prior Year Provision For Contractual Adjustments
PriorYearProvisionForContractualAdjustments
0 usd
CY2023Q1 agio Prior Year Provisions For Rebate Reserve
PriorYearProvisionsForRebateReserve
0 usd
CY2023Q1 agio Provision For Right To Recover Product In Prior Years
ProvisionForRightToRecoverProductInPriorYears
0 usd
CY2023Q1 agio Contract With Customer Prior Years Reserve Provisions
ContractWithCustomerPriorYearsReserveProvisions
0 usd
CY2023Q1 agio Contract With Customer Contract Adjustment Recoveries Current Year
ContractWithCustomerContractAdjustmentRecoveriesCurrentYear
233000 usd
CY2023Q1 agio Contract With Customer Rebate Reserve Recoveries In Current Year
ContractWithCustomerRebateReserveRecoveriesInCurrentYear
0 usd
CY2023Q1 agio Contract With Customer Right To Recover Product Current Year Recoveries
ContractWithCustomerRightToRecoverProductCurrentYearRecoveries
0 usd
CY2023Q1 agio Contract With Customer Current Year Reserve Recoveries
ContractWithCustomerCurrentYearReserveRecoveries
233000 usd
CY2023Q1 agio Contract With Customer Contract Adjustment Recoveries Prior Year
ContractWithCustomerContractAdjustmentRecoveriesPriorYear
48000 usd
CY2023Q1 agio Contract With Customer Rebate Reserve Recoveries In Prior Years
ContractWithCustomerRebateReserveRecoveriesInPriorYears
288000 usd
CY2023Q1 agio Contract With Customer Right To Recover Product Prior Year Recoveries
ContractWithCustomerRightToRecoverProductPriorYearRecoveries
0 usd
CY2023Q1 agio Contract With Customer Prior Years Reserve Recoveries
ContractWithCustomerPriorYearsReserveRecoveries
336000 usd
CY2023Q1 agio Contract With Customer Contractual Adjustment Reserve
ContractWithCustomerContractualAdjustmentReserve
75000 usd
CY2023Q1 agio Contract With Customer Rebate Reserve
ContractWithCustomerRebateReserve
703000 usd
CY2023Q1 agio Contract With Customer Right To Recover Product Reserve
ContractWithCustomerRightToRecoverProductReserve
197000 usd
CY2023Q1 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
975000 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
69000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
60000 usd
CY2023Q1 agio Contract With Customer Allowance And Reserves Liability
ContractWithCustomerAllowanceAndReservesLiability
906000 usd
CY2022Q4 agio Contract With Customer Allowance And Reserves Liability
ContractWithCustomerAllowanceAndReservesLiability
711000 usd
CY2023Q1 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
975000 usd
CY2022Q4 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
771000 usd
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2206000 usd
CY2023Q1 agio Contract With Customer Asset Revenue Recognized
ContractWithCustomerAssetRevenueRecognized
6382000 usd
CY2023Q1 agio Contract With Customer Asset Proceeds From Collection Of Receivables
ContractWithCustomerAssetProceedsFromCollectionOfReceivables
6810000 usd
CY2023Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
1778000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5772564 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
48.81
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
631679 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
25.67
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
131486 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.78
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
302871 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
54.77
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5969886 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
46.91
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3448569 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
58.53
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5969886 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
46.91
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10139000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15510000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10139000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15510000 usd
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7515831 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6571153 shares

Files In Submission

Name View Source Status
0001439222-23-000065-index-headers.html Edgar Link pending
0001439222-23-000065-index.html Edgar Link pending
0001439222-23-000065.txt Edgar Link pending
0001439222-23-000065-xbrl.zip Edgar Link pending
agio-20230331.htm Edgar Link pending
agio-20230331.xsd Edgar Link pending
exhibit101.htm Edgar Link pending
exhibit31-1x03x31x23.htm Edgar Link pending
exhibit31-2x03x31x23.htm Edgar Link pending
exhibit32-1x03x31x23.htm Edgar Link pending
exhibit32-2x03x31x23.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
agio-20230331_cal.xml Edgar Link unprocessable
agio-20230331_def.xml Edgar Link unprocessable
agio-20230331_lab.xml Edgar Link unprocessable
agio-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
agio-20230331_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending